Our risk score holds promising clinical application prospects, and further research on the model's constituent genes, including KPNA2, RRAGC, SPP1, FTCD, ADH4, and ANXA10, could shed light on the mechanism of immune escape, potentially improving the response rate of patients with HCC to immunotherapy. This evidence concerns the gene SPP1 and hepatocellular carcinoma.